Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Molecules (Basel, Switzerland)|October 13, 2021
Solvent Mixture Optimization in the Extraction of Bioactive Compounds and Antioxidant Activities from Garlic (Allium sativum L.)Vytória Piscitelli Cavalcanti, Smail Aazza, Suzan Kelly Vilela Bertolucci, et al.
Environmental Science and Pollution Research International|January 19, 2022
Eugenia uniflora, Melaleuca armillaris, and Schinus molle essential oils to manage larvae of the filarial vector Culex quinquefasciatus (Diptera: Culicidae)Júlia Assunção de Castro Oliveira, Lorena Sales Ferreira, Israel Pereira Garcia, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 6, 2024
Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort StudySammy Huygens, Corine GeurtsvanKessel, Arvind Gharbharan, et al.
Annals of the Rheumatic Diseases|April 28, 2016
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension studyWon Park, Dae Hyun Yoo, Pedro Miranda, et al.
Annals of the Rheumatic Diseases|May 21, 2013
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyDae Hyun Yoo, Pawel Hrycaj, Pedro Miranda, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2024
Risk of Non-AIDS-Defining Events Is Lower in Antiretroviral Therapy (ART)-Naive HIV Controllers Than in Normal Progressors on Suppressive ARTAlbert L Groenendijk, Pedro Miranda Afonso, Ferdinand W N M Wit, et al.
Annals of the Rheumatic Diseases|February 19, 2017
A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritisGerd R Burmester, Iain B McInnes, Joel Kremer, et al.
Annals of the American Thoracic Society|September 8, 2025
Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies After Rapid Adoption: A Dual-Approach StudyPedro Miranda Afonso, Grace C Zhou, Weiji Su, et al.
AIDS (London, England)|May 24, 2024
Immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV in the NetherlandsMarlou J Jongkees, Ngoc H Tan, Daryl Geers, et al.
Rheumatology (Oxford, England)|June 12, 2019
Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trialSeung Cheol Shim, Ljubinka Božić-Majstorović, Alfredo Berrocal Kasay, et al.
Pageof 8